Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGB | P11216 | 7/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | CA12 | O43570 | 3/20 | 0.49 |
| ▸ | CA1 | P00915 | 3/20 | 0.49 |
| ▸ | CA2 | P00918 | 3/20 | 0.49 |
| ▸ | CA9 | Q16790 | 3/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3801496 | 1.00 | PYGB (0.51) | PYGBGAACA12CA1CA2 | |
| SCHEMBL27997210 | 1.00 | PYGB (0.51) | PYGBGAACA12CA1CA2 | |
| SCHEMBL2012475 | 1.00 | PYGB (0.51) | PYGBGAACA12CA1CA2 | |
| SCHEMBL867964 | 1.00 | PYGB (0.51) | PYGBGAACA12CA1CA2 | |
| SCHEMBL28419458 | 1.00 | PYGB (0.51) | PYGBGAACA12CA1CA2 | |
| SCHEMBL29550937 | 0.98 | PYGB (0.49) | PYGBGAACA12CA1CA2 | |
| SCHEMBL7048684 | 0.87 | PYGB (0.49) | PYGBGAACA12CA1CA2 | |
| SCHEMBL2848040 | 0.86 | PYGB (0.44) | PYGBGAACA12CA1CA2 | |
| SCHEMBL4006332 | 0.86 | PYGB (0.44) | PYGBGAACA12CA1CA2 | |
| SCHEMBL670576 | 0.86 | PYGB (0.44) | PYGBGAACA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200131231-A1 | CELL PENETRATING PEPTIDES | UNITED KINGDOM RESEARCH AND INNOVATION (GB) | 2020-04-30 | — | — | US | claimed |
| WO-2018150196-A1 | CELL PENETRATING PEPTIDES MODIFIED BY GLYCOSYLATION | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2018-08-23 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200131231-A1 | CELL PENETRATING PEPTIDES | SLC3A2, ARGLU1, SLC1A5 | PYGB 48/4885GAA 707/4885CA12 2207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.